Facebook
X
LinkedIn
Forward| Title | Credit | Series date | Member price |
Non-member price |
|---|---|---|---|---|
|
Leucovorin in Autism: An Evidence-Based and Clinically Informed Approach 1.25 NAPNAP Contact Hours of which 1.25 contains pharmacology content. This continuing education activity is offered free for NAPNAP Members and non-members. This presentation synthesizes the evidence on folinic acid in autism, with an emphasis on advances since 2018 within the context of foundational work. We will examine the pathophysiology of cerebral folate deficiency (CFD), clarify genetic contributors (e.g., FOLR1 and folate-pathway variants), and review clinical testing with folate receptor-α autoantibodies and related labs. Practical treatment guidance will cover formulation selection, dosing and titration, monitoring, adverse effects, and pharmacy/compounding and cost considerations. Taught by a clinician with extensive real-world experience, the presentation highlights where the evidence is strongest and how to implement it. Learners will finish with a concise, evidence-based framework for evaluating and managing CFD in autism within standard practice. |
|
11/12/2025 to 11/30/2027 | $0.00 | $0.00 |
|
Increasing Access to Mental Health Care in Massachusetts 0.5 NAPNAP Contact Hour. This continuing education activity is free for NAPNAP Members and non-members. This project is supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) and is specific for those interested in increasing access to mental health care in Massachusetts. |
|
07/19/2024 to 12/31/2026 | $0.00 | $0.00 |
|
RSV 2024-2025 – Is Your Pediatric Practice Ready? 1.0 NAPNAP Contact Hour of which 0.75 contain pharmacology content. This continuing education activity is free to National Association of Pediatric Nurse Practitioners (NAPNAP) members and non-members. This course will provide the necessary education enabling pediatric practice providers and staff to successfully prevent RSV in the most vulnerable pediatric populations using the recommendations to administer the appropriate RSV prevention to infants based on weight, age, pre-term birth history, presence of chronic conditions and race. |
|
10/10/2024 to 10/31/2026 | $0.00 | $0.00 |
|
Guidance for Implementing the AAP's 2023 Clinical Practice Guideline for the Evaluation and Treatment of Pediatric Obesity in Primary Care 1.00 NAPNAP Contact Hour. This course is an archived session from NAPNAP's Pediatric Virtual Symposium: 2024 Targeted Topics. The 2023 American Academy of Pediatrics (AAP) CPG for the Evaluation and Treatment of Obesity in Children and Adolescents recommends that children 2-18 years with overweight/obesity be comprehensively evaluated for comorbidities and offered multicomponent, family-based, Intensive Health Behavior and Lifestyle Treatment (IHBLT). This session will focus on the core components of IHBLT and the associated health outcomes. Additionally, participants will learn how to locate recognized Family Healthy Weight Programs and steps to take if there are no local programs. Led by a member of the AAP clinical practice guideline writing team and a member of the NAPNAP Childhood Obesity SIG, this session will help primary care providers assess and build their capacity around IHBLT. |
|
11/15/2024 to 11/30/2026 | $0.00 | $0.00 |
|
Hidden in Plain Sight: Uncovering Cytomegalovirus (CMV) for the Pediatric NP 0.75 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and non-members. |
|
02/17/2025 to 01/31/2027 | $0.00 | $0.00 |
|
Emerging Health Threats in Infants: Perinatal Hepatitis C 0.75 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and non-members. Emerging Health Threats in Infants: Perinatal Hepatitis C. |
|
02/17/2025 to 01/31/2027 | $0.00 | $0.00 |
|
Emerging Health Threats in Infants: Congenital Syphilis 0.75 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and non-members. Emerging Health Threats in Infants: Congenital Syphilis |
|
04/08/2025 to 04/30/2027 | $0.00 | $0.00 |
|
Pharmacologic Management of Cardiac Dysrhythmias 1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. This presentation will focus on the treatment of common dysrhythmias seen in children, specifically pharmacologic options. We will review both inpatient and outpatient management of various dysrhythmias. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
2025 Psychopharmacology Update 2.75 NAPNAP Contact Hour of which 2.75 pharmacology content, 2.75 are Psychopharmacology content and 0.25 are Controlled Substance content. This archived presentation from our 2025 national conference is available only as part of a bundle of pharmacology courses recorded during our 2025 conference in Chicago. Purchase the 2025 Pediatric Pharmacology Bundle and gain access to all five courses. Children and adolescents with behavioral health conditions are commonly seen in all pediatric environments. We will focus on the emerging use of long-acting formulations for management of chronic psychiatric conditions and other new pharmacologic approaches to behavioral health management. This presentation is solely focused on pharmacology and aims to help demystify these medications for the pediatric provider. NAPNAP’s Developmental Behavioral and Mental Health SIG is pleased to support this session. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
New Pediatric Antibiotic Prescribing Guidelines 1.00 NAPNAP Contact Hour of which 1.00 pharmacology content. This archived presentation from our 2025 national conference is available only as part of a bundle of pharmacology courses recorded during our 2025 conference in Chicago. Purchase the 2025 Pediatric Pharmacology Bundle and gain access to all five courses. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Keeping Current in Atopic Diseases 1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. The field of Allergy & Immunology continues to expand and incorporate new therapeutics to manage difficult diseases. In 2024, new drugs have been approved that can revolutionize treatment for disease management. Patients will look to their primary care clinicians to be knowledgeable and a resource for these therapeutics. This panel will include three NP experts from food allergy centers at the Children’s Hospital of Philadelphia and University of Texas Southwestern and will discuss biologics, immunotherapy options and non-IgE mediated disease updates for food allergy. NAPNAP’s Asthma and Allergy SIG is pleased to support this session. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Influenza 2025-2026: Is Your Pediatric Practice Ready? 1.0 NAPNAP Contact Hour of which 0.75 contain pharmacology content. This continuing education activity is offered free for NAPNAP Members and non-members. As we enter influenza season, pediatric-focused APRNs can increase their knowledge and prepare to counsel families and restore confidence in influenza vaccines. This continuing education presentation will teach providers to balance communication of scientific data and vaccine efficacy with acknowledgment of parental concerns and fears, and help families feel empowered to make the best decisions when it comes to flu prevention. |
|
11/14/2025 to 11/30/2026 | $0.00 | $0.00 |
|
What Are You Taking? Hot Topics in Herbal Supplementations 1.25 NAPNAP contact hours of which 0.5 pharmacology content. This continuing education activity is offered as part of the Pediatric Pharmacology Bundle. This course is a record presentation for NAPNAP's 2026 National Conference. About a third of all children ingest some type of supplementations most being multivitamins and this number is increasing. Social media has provided avenues to learn and experiment with supplements. Only five percent of patients discuss supplements with a provider prior to starting. This presentation will provide guidance on resources for providers to use for supplementation education and review common supplements that might be used in pediatrics. |
|
07/01/2026 to 06/30/2028 | $0.00 | $0.00 |
|
Pharmacogenomics: Emerging trends in pediatric personalized medicine 1.25 NAPNAP contact hours of which 1.25 pharmacology content. This continuing education activity is offered as part of the Pediatric Pharmacology Bundle. This course is a record presentation for NAPNAP's 2026 National Conference. Pharmacogenomics, the science of evaluating the effects of genetic variants on one's response to treatment, allows for delivery of personalized medicine in pediatric patients. Emerging trends in pediatrics for pharmacogenomic testing include cardiology, asthma, cystic fibrosis, leukemias, rheumatologic disorders and more. The use of pharmacogenomic testing in mental health disorders has widely been described elsewhere. |
|
07/01/2026 to 06/30/2028 | $0.00 | $0.00 |
|
Pediatric Psychopharmacology Update 2026 1.00 NAPNAP contact hour of which 1.00 pharmacology content, 1.00 psychopharmacology content and 0.25 controlled substance content. This continuing education activity is offered as part of the Pediatric Pharmacology Bundle. This course is a record presentation for NAPNAP's 2026 National Conference. Evidence shows that pediatric primary and specialty care providers are often challenged by the management of pediatric patients with mental and behavioral health conditions. This presentation provides an update on recent advances in pediatric psychopharmacology, focusing on the safe and effective use of psychiatric medications in children and adolescents. With an emphasis on evidence-based treatment strategies, we will review updated guidelines, emerging research on medication use and newly approved medications for use in pediatrics. Special attention will be given to the management of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), including the use of stimulants, non-stimulant ADHD medications, and SSRIs. We will also address strategies to enhance adherence and monitoring and challenges faced when choosing specific agents, including tips for dealing with the complexities of obtaining prior authorizations.. Participants will gain practical insights to optimize pharmacologic treatment plans within an integrated, patient-centered approach to improve pediatric mental health care. |
|
07/01/2026 to 06/30/2028 | $0.00 | $0.00 |